No Data
UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy
UniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $12
UniQure N.V. (NASDAQ:QURE) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $28
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $9
No Data
No Data